文献速递免疫规划

小分子IRF3激动剂通过调节抗病毒免疫反应发挥流感疫苗佐剂作用

A small-molecule IRF3 agonist functions as an influenza vaccine adjuvant by modulating the antiviral immune response.
PubMed 文献 · Vaccine · 2017-03-06

研究通过高通量筛选发现苯并噻唑类化合物KIN1148可激活IRF3,将其与亚 Optimal 剂量单价大流行流感裂解病毒H1N1 A/California/07/2009疫苗联合免疫小鼠,可抵抗致死性攻击并诱导IL-10和Th2反应;单次免疫联合KIN1148较单用疫苗提供更好保护并降低肺内病毒载量。

要点

  • KIN1148诱导剂量依赖性IRF3核转位并激活IRF3响应启动子。
  • 加强免疫联合KIN1148可抵抗致死性攻击并诱导抗原特异性IL-10和Th2反应。
  • 单次免疫联合KIN1148较单用疫苗提高保护并降低攻毒后肺内病毒载量。

核心结论

  • 保护至少部分由细胞免疫成分介导,KIN1148佐剂疫苗诱导Th2和免疫调节细胞因子可能有助于改善流感病毒相关免疫病理。

研究设计与样本

  • 采用高通量筛选发现RIG-I样受体通路小分子激动剂,从苯并噻唑化合物设计先导类似物KIN1148,并在小鼠中进行初免-加强或单次免疫评估。

主要发现

  • KIN1148诱导剂量依赖性IRF3核转位和IRF3响应启动子的特异性激活。
  • 小鼠初免-加强免疫亚 Optimal 剂量单价大流行流感裂解病毒H1N1 A/California/07/2009疫苗加KIN1148,可抵抗小鼠适应流感病毒A/California/04/2009致死性攻击,并诱导肺和肺引流淋巴结T细胞产生流感病毒特异性IL-10和Th2反应。
  • 疫苗加KIN1148初免-加强免疫而非单独初免,诱导可抑制流感病毒血凝素并中和病毒感染性的抗体。
  • 单次免疫疫苗加KIN1148较单用疫苗提供更高保护并降低攻毒后肺内病毒载量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vaccine adjuvants are essential to drive a protective immune response in cases where vaccine antigens are weakly immunogenic, where vaccine antigen is limited, or where an increase in potency is needed for a specific population, such as the elderly. To discover novel vaccine adjuvants, we used a high-throughput screen (HTS) designed to identify small-molecule agonists of the RIG-I-like receptor (RLR) pathway leading to interferon regulatory factor 3 (IRF3) activation. RLRs are a group of cytosolic pattern-recognition receptors that are essential for the recognition of viral nucleic acids during infection. Upon binding of viral nucleic acid ligands, the RLRs become activated and signal to transcription factors, including IRF3, to initiate an innate immune transcriptional program to control virus infection. Among our HTS hits were a series of benzothiazole compounds from which we designed the lead analog, KIN1148. KIN1148 induced dose-dependent IRF3 nuclear translocation and specific activation of IRF3-responsive promoters. Prime-boost immunization of mice with a suboptimal dose of a monovalent pandemic influenza split virus H1N1 A/California/07/2009 vaccine plus KIN1148 protected against a lethal challenge with mouse-adapted influenza virus (A/California/04/2009) and induced an influenza virus-specific IL-10 and Th2 response by T cells derived from lung and lung-draining lymph nodes. Prime-boost immunization with vaccine plus KIN1148, but not prime immunization alone, induced antibodies capable of inhibiting influenza virus hemagglutinin and neutralizing viral infectivity. Nevertheless, a single immunization with vaccine plus KIN1148 provided increased protection over vaccine alone and reduced viral load in the lungs after challenge. These findings suggest that protection was at least partially mediated by a cellular immune component and that the induction of Th2 and immunoregulatory cytokines by a KIN1148-adjuvanted vaccine may be particularly beneficial for ameliorating the immunopathogenesis that is associated with influenza viruses.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Probst P, Grigg JB, Wang M, et al. A small-molecule IRF3 agonist functions as an influenza vaccine adjuvant by modulating the antiviral immune response. Vaccine. 2017. PMID: 28279563. doi:10.1016/j.vaccine.2017.01.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。